A PATIENT WALKED INTO CLINIC LAST WEEK & SAID SOMETHING I HEAR CONSTANTLY
 
I'm doing everything right. Why isn't anything working?
 
She’s 48. Over the last three years, she gained about 30 pounds despite tracking macros, working out five days a week, and sleeping well.
 
Her previous doctor’s advice was familiar. Eat less. Move more.
She was already eating around 1,700 calories and running every day.
I looked at her labs: 
  • Fasting insulin: 18
  • Triglycerides: 220
  • HDL: 38
  • Fasting glucose: 117
 
The pattern was clear. Insulin resistance, perimenopausal
She wasn’t lazy.
She wasn’t undisciplined.
She was metabolically stuck.
 
 
Midlife weight gain isn't a moral failing. It's a metabolic shift that requires a different approach.
 
Hi First name / there, let's talk about this.
 
If you’ve felt unsure or skeptical about GLP-1 medications, that makes sense.
There is a lot of noise out there. Headlines taken out of context. Social media clips. Clinics prescribing these medications quickly, with very little explanation. Most patients who come into my office have the same questions.
  • Will I be on this forever?
  • I don’t like taking medications. Is this really necessary?
  • What does this do long term?
  • Am I going to lose muscle or look gaunt?
  • What happens when I stop?
These are thoughtful, reasonable concerns. They deserve clear answers.
 
One thing is important to say early.
The issue is not the medication itself. It’s how, and in what context, it’s used.
Image item
 
Where the Science Is Headed
 
GLP-1 medications are not a finished story 
 
Recent Phase 2 data on retatrutide—a triple agonist targeting GLP-1, GIP, and glucagon receptors—were published in NJEM. These studies followed adults with obesity for up to 48 weeks and revealed outcomes that extend well beyond appetite suppression.
 
At higher doses, participants experienced average weight loss approaching 24%, along with meaningful reductions in waist circumference, triglycerides, and markers of insulin resistance. 
 
By acting on multiple hormonal pathways, retatrutide appears to influence energy expenditure, fat distribution, insulin sensitivity, and lipid metabolism, not simply hunger. This reinforces a growing understanding in endocrinology: obesity and metabolic dysfunction are multi-system conditions, not failures of willpower or isolated appetite problems.
 
As therapies become more powerful and more complex, the clinical stakes rise. 
 
Greater efficacy means we must pay closer attention to how weight is lost, not just how much. Muscle preservation, protein intake, micronutrient status, bone health, and cardiometabolic monitoring become essential, not optional. 
 
Dosing strategies matter. Timing matters. Context matters.
The future of metabolic care isn’t about chasing the newest medication. It’s about precision: choosing the right tool, for the right patient, with the right safeguards in place. And that requires care that evolves alongside the science.
 
What GLP-1 Medications do?
 
GLP-1–based medications act on hormone pathways involved in satiety, insulin signaling, and glucose regulation.
 
In patients with insulin resistance, those pathways are dysregulated. Hunger signals are amplified. Satiety signals are blunted. Glucose handling is inefficient.
 
When these medications are working appropriately, patients typically notice:
  • Feeling full sooner and staying full longer
  • Less constant mental pull toward food
  • More stable energy and glucose patterns
  • Improvement in metabolic labs over time
That is the intended effect.
 
Plateaus are common
 
Weight loss plateaus happen on GLP-1 medications. They do not automatically mean failure.
In practice, plateaus usually reflect one or more of the following:
  • Metabolic adaptation as weight decreases
  • Loss of lean mass contributing to lower energy expenditure
  • Protein intake that no longer matches body composition needs
  • Insufficient strength training
  • A dose that no longer aligns with physiologic response
Some of this is normal biology.
Some of it is modifiable.
 
The difference is whether it’s recognized and addressed.
 
 
 
Cost, Access & Clinical Appropriateness

Coverage is evolving rapidly. Medicare coverage for obesity is expected mid-2026, with projected copays around $50, while private insurance coverage varies by plan and indication. Manufacturer assistance programs typically range from $199 to $499 per month. 
 
If cost is a barrier, we discuss all available options during your initial consultation.
 
GLP-1–based therapy may be appropriate if you meet the following criteria: BMI ≥27 with weight-related comorbidities or BMI ≥30; evidence of metabolic dysfunction such as insulin resistance, prediabetes, type 2 diabetes, or dyslipidemia; history of weight regain despite sustained lifestyle modification; or significant metabolic changes associated with perimenopause or menopause. 
 
Treatment decisions are based on your complete metabolic profile, medical history, and treatment goals.
 
BACK TO THE STORY

My patient's success
 
Eight months later:
Weight down 22 pounds
Fasting glucose improved from 117 to 88
Triglycerides dropped from 220 to 118
Blood pressure normalized
 
What mattered most to her wasn’t the scale.
She said, “I finally feel like I can think about my life again, not just food.”
 
That’s metabolic health.
 
 
Image item
Looking forward to partnering in your metabolic health.
Dr. Sobia Sadiq
 
Visit our Facebook
Visit our Instagram
Visit our LinkedIn
 
119 E. Odgen Avenue, Suite 211C
Hinsdale, IL 60521, United States

Unsubscribe or Manage Preferences here. No hard feelings!